Kelly CRISPR & Gene Editing Technology ETF
Limited financial coverage for XDNA.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
About the company
The fund employs a passive investment strategy, aiming to replicate the total return performance of its benchmark index. This index is rule-based, comprising equities or their corresponding depositary receipts from companies involved in the entire spectrum of DNA Modification Technology, including its invention, advancement, production, operation, provision, distribution, ownership, maintenance, licensing, leasing, or franchising. A minimum of 80% of the fund's net assets are dedicated to enterprises focused on DNA Modification Technology.
- IPO
- 2022
Price Chart
- Market Cap
- $2.58M
- Div Yield
- 0.13%
- 52W High
- $11.83
- 52W Low
- $5.87
- 50D MA
- $7.01
- 200D MA
- $8.43
- Beta
- 0.00
- Avg Volume
- 5.04K
Get TickerSpark's AI analysis on XDNA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our XDNA coverage
Recent articles, reports, and earnings notes.
No research on XDNA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate XDNA report →Similar companies
Peers in the same neighborhood.